Journal of Clinical Endocrinology & Metabolism, Vol 76, 1399-1406, Copyright © 1993 by Endocrine Society

ARTICLES

The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women

ST Harris, BJ Gertz, HK Genant, DR Eyre, TT Survill, JN Ventura, J DeBrock, E Ricerca and CH Chesnut 3d
Department of Medicine, University of California, San Francisco 94143.

The effects of oral alendronate treatment on spinal bone mineral density and biochemical markers of bone turnover were assessed in women in the early postmenopausal period. Sixty-five women were treated with placebo or 5, 20, or 40 mg alendronate daily for 6 weeks in a double blind study. Treatment with alendronate decreased both urinary markers of bone resorption (pyridinolines, hydroxyproline, and calcium) and serum markers of bone formation (osteocalcin and alkaline phosphatase) in a dose-dependent fashion. This short term treatment with alendronate also produced a dose-dependent increase in lumbar bone mineral density measured 7.5 months after the completion of therapy. Median percent changes in integral spinal bone mineral density, as assessed by dual x- ray absorptiometry, were -2.3, -1.2, +0.7, and +1.2 after treatment with placebo and 5, 20, and 40 mg alendronate, respectively. Treatment with alendronate was well tolerated and produced no fever; gastrointestinal intolerance was no more common than with placebo treatment. Short term alendronate treatment in early postmenopausal women decreased bone turnover and increased vertebral density.

This article has been cited by other articles:

				A. Grey, S. O'Sullivan, I. R. Reid, and P. Browett Imatinib Mesylate, Increased Bone Formation, and Secondary Hyperparathyroidism N. Engl. J. Med., December 7, 2006; 355(23): 2494 - 2495. [Full Text] [PDF]

				C.-J. Wang, J.-W. Wang, J.-Y. Ko, L.-H. Weng, and C.-C. Huang Three-Year Changes in Bone Mineral Density Around the Knee After a Six-Month Course of Oral Alendronate Following Total Knee Arthroplasty. A Prospective, Randomized Study J. Bone Joint Surg. Am., February 1, 2006; 88(2): 267 - 272. [Abstract] [Full Text] [PDF]

				L Maimoun, D Simar, D Malatesta, C Caillaud, E Peruchon, I Couret, M Rossi, and D Mariano-Goulart Response of bone metabolism related hormones to a single session of strenuous exercise in active elderly subjects Br. J. Sports Med., August 1, 2005; 39(8): 497 - 502. [Abstract] [Full Text] [PDF]

				C. V. Odvina, J. E. Zerwekh, D. S. Rao, N. Maalouf, F. A. Gottschalk, and C. Y. C. Pak Severely Suppressed Bone Turnover: A Potential Complication of Alendronate Therapy J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1294 - 1301. [Abstract] [Full Text] [PDF]

				A. Cranney, G. Wells, A. Willan, L. Griffith, N. Zytaruk, V. Robinson, D. Black, J. Adachi, B. Shea, P. Tugwell, et al. II. Meta-Analysis of Alendronate for the Treatment of Postmenopausal Women Endocr. Rev., August 1, 2002; 23(4): 508 - 516. [Full Text] [PDF]

				R. J Maclsaac, E. Seeman, and G. Jerums Seizures after alendronate J R Soc Med, January 12, 2002; 95(12): 615 - 616. [Full Text] [PDF]

				J. H. Tobias, S. Clarke, K. Mitchell, S. Robins, H. Amer, and W. D. Fraser Analysis of the Contribution of Dydrogesterone to Bone Turnover Changes in Postmenopausal Women Commencing Hormone Replacement Therapy J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1194 - 1198. [Abstract] [Full Text]

				S. L. Greenspan, H. N. Rosen, and R. A. Parker Early Changes in Serum N-Telopeptide and C-Telopeptide Cross-Linked Collagen Type 1 Predict Long-Term Response to Alendronate Therapy in Elderly Women J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3537 - 3540. [Abstract] [Full Text]

				P. Ravn, M. Bidstrup, R. D. Wasnich, J. W. Davis, M. R. McClung, A. Balske, C. Coupland, O. Sahota, A. Kaur, M. Daley, et al. Alendronate and Estrogen-Progestin in the Long-Term Prevention of Bone Loss: Four-Year Results from the Early Postmenopausal Intervention Cohort Study: A Randomized, Controlled Trial Ann Intern Med, December 21, 1999; 131(12): 935 - 942. [Abstract] [Full Text] [PDF]

				M. Sarno, H. Powell, G. Tjersland, D. Schoendorfer, H. Harris, K. Adams, P. Ogata, and G. R. Warnick A Collection Method and High-Sensitivity Enzyme Immunoassay for Sweat Pyridinoline and Deoxypyridinoline Cross-Links Clin. Chem., September 1, 1999; 45(9): 1501 - 1509. [Abstract] [Full Text] [PDF]

				P. Ravn, D. Hosking, D. Thompson, G. Cizza, R. D. Wasnich, M. McClung, A. J. Yates, N. H. Bjarnason, and C. Christiansen Monitoring of Alendronate Treatment and Prediction of Effect on Bone Mass by Biochemical Markers in the Early Postmenopausal Intervention Cohort Study J. Clin. Endocrinol. Metab., July 1, 1999; 84(7): 2363 - 2368. [Abstract] [Full Text]

				P. Bettica, M. Bevilacqua, T. Vago, M. Masino, E. Cucinotta, and G. Norbiato Short-Term Variations in Bone Remodeling Biochemical Markers: Cyclical Etidronate and Alendronate Effects Compared J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 3034 - 3039. [Abstract] [Full Text] [PDF]

				J. H TOBIAS How do bisphosphonates prevent fractures? Ann Rheum Dis, September 1, 1997; 56(9): 510 - 511. [Full Text]

				S. Patel, D. Pearson, A. Bhallah, W. Maslanka, D. A White, and D. J Hosking Changes in bone mineral density in patients with Paget's disease treated with risedronate Ann Rheum Dis, July 1, 1997; 56(7): 405 - 409. [Abstract] [Full Text]

				H. G. Bone, R. W. Downs Jr., J. R. Tucci, S. T. Harris, R. S. Weinstein, A. A. Licata, M. R. McClung, D. B. Kimmel, B. J. Gertz, E. Hale, et al. Dose-Response Relationships for Alendronate Treatment in Osteoporotic Elderly Women J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 265 - 274. [Abstract] [Full Text] [PDF]